Vivimed Labs Limited is in Corporate Insolvency Resolution Process (CIRP) as of April 15, 2026. The company reported a consolidated net loss of ₹176.47 crore for FY26. Auditors issued a qualified opinion highlighting issues with interest recognition and balances.
Vivimed Labs Enters CIRP Amidst Severe Financial Distress
Consolidated Net Loss: ₹176.47 crore Consolidated Revenue: ₹69.99 crore Reader Takeaway: Company in insolvency proceedings with qualified audit findings and deep losses; future uncertain. ## What just happened Vivimed Labs Limited has officially entered the Corporate Insolvency Resolution Process (CIRP) as of April 15, 2026. This follows an order from the National Company Law Tribunal (NCLT). The company's Board of Directors has been suspended, and control has been transferred to an Interim Resolution Professional (IRP). ## Why this matters The CIRP signifies a critical stage for Vivimed Labs, indicating severe financial difficulties. The suspension of the board and the IRP's control mean a fundamental shift in management and strategy. For shareholders, this process introduces significant uncertainty regarding the company's future and the potential recovery of their investments. ## The backstory Vivimed Labs has reported a significant financial erosion for the fiscal year ended March 31, 2026. The consolidated net loss stands at ₹176.47 crore, with consolidated revenue at ₹69.99 crore. Both standalone and consolidated figures reveal deep losses, pushing the company's net worth into negative territory. ## What changes now With the company under CIRP, the focus shifts to the resolution process managed by the IRP. The objective is to find a viable solution to revive the company or liquidate its assets. The suspended Board of Directors will no longer have any powers. ## Risks to watch - **Regulatory:** The company is under CIRP, a major regulatory proceeding. - **Legal:** A CBI investigation is also disclosed by the management. - **Financial:** Auditors have issued a qualified opinion on the financial statements. - **Financial:** Negative equity indicates substantial erosion of net worth. ## Auditor's Qualified Opinion The statutory auditors have raised several critical concerns in their report: - Failure to recognize approximately ₹62.57 crore in interest expenses on an accrual basis. - Inability to obtain direct external confirmations for borrowings, creating uncertainty about their accuracy. - Lack of balance confirmations for creditors, debtors, and financial liabilities hindering audit verification. - Uncertainty regarding the recoverability of ₹37.27 crore classified as 'Other Advances'. ## Management Commentary Despite these challenges, the management has expressed confidence that the company can continue operations and meet its obligations. They cite ongoing business plans, promoter support, and anticipated operational improvements as reasons for this optimism. ## Context metrics (time-bound) - CIRP Start Date: April 15, 2026 - Fiscal Year End: March 31, 2026 - Consolidated Revenue (FY26): ₹69.99 crore - Consolidated Net Loss (FY26): ₹176.47 crore - Standalone Revenue (FY26): ₹55.78 crore - Standalone Net Loss (FY26): ₹(171.61) crore - Total Assets (Standalone FY26): ₹502.16 crore - Total Equity (Standalone FY26): ₹(112.19) crore - Total Assets (Consolidated FY26): ₹753.48 crore - Total Equity (Consolidated FY26): ₹(210.55) crore - Unrecognized Interest Expense: ₹62.57 crore - Other Advances Uncertainty: ₹37.27 crore ## What to track next Investors should closely monitor updates from the Interim Resolution Professional regarding the progress of the CIRP and any potential resolution plans. Information regarding the CBI investigation and any further actions will also be crucial.
